DISCLAIMER— Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Planet Labs PBC ( $PL )
Planet Labs—not NVIDIA—officially announced on March 16, 2026 that it is building a GPU-native AI engine for planetary intelligence with NVIDIA. The news matters not because it creates a completely new Planet story, but because it reinforces a strategic transition Merlintrader had already identified: Planet is moving beyond raw imagery delivery toward a faster, higher-value geospatial intelligence layer built on AI processing, semantic search and real-time operational utility.
By Merlintrader | Updated March 17, 2026
Olema Pharmaceuticals Inc ( $OLMA ) deep dive march 17 2026
Olema sits in one of the most interesting transition zones in clinical-stage biotech. It is no longer a company that can be dismissed as little more than a speculative preclinical story, because it now has a late-stage development strategy centered on palazestrant, a second clinical engine in OP-3136, and a balance sheet that looks strong enough to bridge the company through several major milestones. At the same time, Olema is not yet a diversified oncology company with multiple independent late-stage assets that can absorb a major failure without a violent valuation reset. That is why the stock remains so fascinating. It offers a genuine setup for a re-rating if execution continues, but it also remains highly exposed to a narrow band of high-information events.
Momentus Inc ( $MNTS )– complete deep dive on the recent timeline, government milestones, customer contracts, backlog signals, cash stress and execution risk
Momentus is one of those small-cap space names that keeps surviving by refusing to stay simple. If you look only at the financial statements, MNTS still looks fragile: revenue is very small, cash remains thin, net losses are large relative to the company’s size, and the latest quarterly filing still explicitly raised substantial doubt about the company’s ability to continue as a going concern. But if you look only at the press releases, you get a different picture: government-linked milestones, NASA work, DARPA-related progress, U.S. Space Force vehicle eligibility, commercial payload partnerships, and a near-term mission that could function as an operational showcase.
Structure Therapeutics Inc ADR ( $GPCR ) DD march 16 2026
Structure Therapeutics was founded with a singular mission: to build a structure-based GPCR (G-protein-coupled receptor) drug discovery platform. The company's name literally reflects its core intellectual property—the belief that understanding the three-dimensional structure of GPCR proteins could enable design of highly selective, potent small molecule drugs that traditional high-throughput screening couldn't easily find.
Annovis Bio ( $ANVS ) – Deep Dive on Buntanetap 2026
Annovis is one of those biotech names that looks tiny on the screen but can become very large in narrative terms whenever the market wants a fresh Alzheimer’s angle. The company’s March 16, 2026 fiscal-year update did not announce an approval, an acquisition or a phase-changing headline readout. What it did provide was something more practical: a clean status check on the one thing that matters most for Annovis today, namely whether its pivotal Alzheimer’s program is moving forward fast enough to keep the investment story alive before the cash window narrows too much.
United States Antimony ( $UAMY ) – Pentagon Demand, Commercial Scale and the 2026 Execution Test
United States Antimony Corporation (NYSE American: UAMY) has positioned itself as a critical-minerals player through two landmark contracts announced in late 2025: a five-year, sole-source IDIQ agreement with the U.S. Defense Logistics Agency worth up to $245 million, and a new five-year commercial supply deal with a major U.S. industrial fabric manufacturer valued at approximately $107 million. Together, these contracts—announced over a 60-day period in September–October 2025—represent combined long-term visibility of up to $352 million.
NRx Pharmaceuticals ( $NRXP ) – FDA Minutes Lock In the NRX-100 NDA Path
NRx Pharmaceuticals finally got the kind of news biotech traders usually wait for: not just another optimistic corporate interpretation, but formal written FDA minutes that document the regulatory path. In today’s release, the company said it received the confirmatory written minutes from its February 17, 2026 in-person Type C meeting with the FDA. According to NRx, those minutes support a path to file an NDA for NRX-100 by June 2026 using existing adequate and well-controlled clinical trial data together with confirmatory Real World Evidence. The company also said the FDA confirmed that no additional clinical trials and no bridging studies are required for the preservative-free formulation
Redwire Corporation ( $RDW )Space infrastructure, defense tech, and execution risk all colliding in 2026
Redwire enters 2026 with a much stronger strategic narrative than it had a year ago. The company is no longer just a small-cap space infrastructure name trying to prove relevance. It now has a larger defense-tech footprint after the Edge Autonomy deal, a more visible sovereign-Europe angle after the Belgian MATTEO award, and a record year-end backlog that gives management a real basis for projecting a major step-up in 2026 revenue.
That is the good side of the story. The harder side is that Redwire still has not earned the right to be treated as a clean execution story. FY2025 showed real top-line progress, but it also exposed how fragile the model remains when development programs run into estimate-at-completion adjustments, integration costs, and heavy cash burn. Revenue grew. Backlog improved. Book-to-bill improved. Yet the company still posted a much larger net loss and very weak free cash flow.
The core question for RDW in 2026 is therefore simple: can Redwire convert strategic relevance into operational credibility? If the answer becomes yes, the stock can look too cheap versus its backlog, government exposure, and 2026 guide. If the answer stays uncertain, the name can remain trapped as an interesting story with inconsistent economics.
POET Technologies Inc ( $POET ) after the LITEON partnership
POET arrived at the industry’s key optical-communications event with fresh news in hand: the new co-development announcement with LITEON, plus demonstrations of Blazar and Starlight products aimed at AI-related optical connectivity. In practical terms, this is the first immediate stage where the market can gauge whether the latest headline gets traction beyond the press release itself.
ROCKET LAB ( $RKLB ) COMPLETE DEEP DIVE march 15 2026
Rocket Lab is no longer just a “small rocket” story. That framing is outdated. The business that reported 2025 results is a broader space infrastructure company with three engines under the hood: Electron launch services, a much larger and increasingly important Space Systems segment, and Neutron, the still-unproven but strategically vital medium-lift program.
Vertex Pharmaceuticals ( $VRTX ) no longer just a cystic fibrosis machine
Vertex Pharmaceuticals remains one of the highest-quality large-cap biotech stories in the market, but the real reason the name deserves a first full Merlintrader deep dive now is not simply scale, profitability or balance-sheet strength. The more important point is that the company has reached a stage where investors can begin to judge whether the long-promised diversification beyond cystic fibrosis is becoming economically meaningful rather than merely aspirational.
Weekly Market Recap & Next Week Prep — March 15, 2026
The week that ended on Friday, March 13, did not deliver a clean “risk-on” or “risk-off” message. It delivered something more difficult and, for active traders, more important: a selective tape in which macro stress was real, energy shock risk was impossible to ignore, but not every pocket of the market reacted in the same way. That distinction matters. A market that falls together can often bounce together. A market that starts separating winners from losers under pressure is usually telling you that stock-picking, catalyst timing and sector choice are starting to matter more than headline beta.
Sidus Space Inc ( $SIDU ) March 14 2026 Deep Dive
Sidus Space Inc (NASDAQ: SIDU) is an innovative space mission enabler operating at the intersection of commercial satellite manufacturing, artificial intelligence-enabled space-based data solutions, and defense technology integration. Founded in 2012 and based on Florida's Space Coast in Merritt Island, the company operates a 35,000-square-foot integrated manufacturing, assembly, and testing facility with direct access to launch infrastructure.
AeroVironment Inc ( $AVAV ) Defense Technology | Uncrewed Systems & Tactical Missiles
AeroVironment (AVAV) operates at the intersection of two powerful secular trends: the electrification and autonomy of military platforms, and the rising geopolitical demand for precision defense systems. As a leader in uncrewed aircraft systems (UAS), loitering munitions (Switchblade series), counter-unmanned aerial systems, and space-based directed energy platforms, the company is uniquely positioned to benefit from a multi-decade modernization cycle driven by conflicts in Ukraine, the Middle East escalation, and NATO expansion.
Satellogic Inc ( $SATL ) Vertically Integrated Earth Observation & Persistent Monitoring March14 DD
Satellogic is one of those names that can look much bigger, much smaller, much safer or much more dangerous depending on the exact week in which an investor or trader meets the story. In a hot tape, the company can be pitched as a pure-play Earth observation platform exposed to sovereign demand, AI-driven geospatial workflows and a possible shift toward more recurring monitoring contracts. In a colder tape, exactly the same company can be described as a low-margin, cash-consuming, serially dilutive small cap whose commercial wins still need to prove that they can scale into a durable business rather than a string of eye-catching press releases. Both sides are seeing a piece of the truth. That is why a SATL report is only useful if it keeps those two realities on the page at the same time.
Intuitive Machines Inc ( $LUNR ) Deep Dive March 14/2026
Intuitive Machines Inc (LUNR) is a diversified space infrastructure company with four core business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products & Infrastructure. Founded in 2013, IM has emerged as a prime contractor for NASA lunar missions, U.S. Department of Defense space architecture programs, and emerging commercial lunar economy players. The company's 2024 milestone—landing the Nova-C lunar lander on the Moon's South Pole region—marked the first crewed-space-capable U.S. lunar return since Apollo 17, positioning IM as the dominant platform for American lunar access for the foreseeable future.
Aldeyra Therapeutics ( $ALDX ): past, present and future around reproxalap and the March 2026 FDA decision
A long-form bilingual deep dive built around the full regulatory arc of Aldeyra, from the first dry-eye filing to the 2025 collapse and the current March 2026 binary setup. The focus here is not only on what happened, but on why the market still cares, what could realistically change if reproxalap is approved, what the damage would look like if it is rejected again, and how retail traders are framing the setup in the final stretch before the decision.
ImmunityBio Inc ( $IBRX ) today’s NK-cell manufacturing milestone is real
Today’s official release from ImmunityBio was about cell-manufacturing execution, not about ANKTIVA sales, not about a fresh FDA approval, and not about a pivotal top-line readout. The company said it has completed manufacturing engineering programs that established a reproducible leukapheresis-to-manufacturing pathway for its autologous M-ceNK platform. In simple English, ImmunityBio is telling the market that it has moved another step from “interesting immunology concept” toward “repeatable cell-therapy process that can be run at scale.”
5 energy stocks under $2 billion to watch in march ( $PUMP $EGY $RNGR $GEOS $KLXE )
This article compares five U.S.-listed energy names below $2 billion in market value that could benefit, directly or indirectly, from a stronger oil tape, firmer field activity, or renewed investor appetite for smaller-cap energy exposure: ProPetro (PUMP), VAALCO Energy (EGY), Ranger Energy Services (RNGR), Geospace Technologies (GEOS) and KLX Energy Services (KLXE).
Immutep Limited ( Nasdaq $IMMP ) after TACTI-004 futility
Core fact
On March 13, 2026 Immutep said the Independent Data Monitoring Committee recommended discontinuing the registrational Phase III TACTI-004 study following the planned futility analysis.
